Katja Klausz

1.0k total citations
49 papers, 780 citations indexed

About

Katja Klausz is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Oncology. According to data from OpenAlex, Katja Klausz has authored 49 papers receiving a total of 780 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Radiology, Nuclear Medicine and Imaging, 30 papers in Immunology and 26 papers in Oncology. Recurrent topics in Katja Klausz's work include Monoclonal and Polyclonal Antibodies Research (38 papers), CAR-T cell therapy research (20 papers) and Immune Cell Function and Interaction (16 papers). Katja Klausz is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (38 papers), CAR-T cell therapy research (20 papers) and Immune Cell Function and Interaction (16 papers). Katja Klausz collaborates with scholars based in Germany, Netherlands and United States. Katja Klausz's co-authors include Matthias Peipp, Christian Kellner, Thomas Valerius, Stefanie Derer, Stefan Lohse, Anna Otte, Martin Gramatzki, Elisa Cappuzzello, Jeanette H.W. Leusen and Michael Dechant and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Katja Klausz

48 papers receiving 766 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Katja Klausz Germany	18	444	382	367	275	69	49	780
Thies Rösner Germany	16	463 1.0×	309 0.8×	202 0.6×	207 0.8×	45 0.7×	30	666
Hsing Chen United States	12	415 0.9×	541 1.4×	218 0.6×	331 1.2×	77 1.1×	18	797
Erik Pong United States	16	484 1.1×	617 1.6×	358 1.0×	433 1.6×	80 1.2×	24	1.1k
Michael Schwenkert Germany	13	422 1.0×	221 0.6×	368 1.0×	265 1.0×	60 0.9×	14	673
Louise W. Treffers Netherlands	9	449 1.0×	317 0.8×	198 0.5×	423 1.5×	58 0.8×	9	809
Paola Porcedda Italy	12	302 0.7×	151 0.4×	250 0.7×	419 1.5×	48 0.7×	17	800
B. Cochlovius Germany	5	748 1.7×	393 1.0×	295 0.8×	579 2.1×	34 0.5×	6	1.0k
Grit Lorenczewski Germany	13	441 1.0×	611 1.6×	746 2.0×	269 1.0×	54 0.8×	17	995
Saskia Meyer Netherlands	11	298 0.7×	242 0.6×	99 0.3×	169 0.6×	40 0.6×	16	454
Ralf Lutterbüse Germany	11	447 1.0×	580 1.5×	681 1.9×	304 1.1×	52 0.8×	13	1.0k

Countries citing papers authored by Katja Klausz

Since Specialization

Citations

This map shows the geographic impact of Katja Klausz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katja Klausz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katja Klausz more than expected).

Fields of papers citing papers by Katja Klausz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katja Klausz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katja Klausz. The network helps show where Katja Klausz may publish in the future.

Co-authorship network of co-authors of Katja Klausz

This figure shows the co-authorship network connecting the top 25 collaborators of Katja Klausz. A scholar is included among the top collaborators of Katja Klausz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katja Klausz. Katja Klausz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Strauß, Julia, Gerrit Wolters‐Eisfeld, Peter Nollau, et al.. (2025). Memory-like Natural Killer Cell and CD19 Antibody–Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia. Cancer Immunology Research. 13(6). 881–896. 1 indexed citations

Krohn, Steffen, Arianne M. Brandsma, Petra Moerer, et al.. (2024). Combining Cellular Immunization and Phage Display Screening Results in Novel, FcγRI-Specific Antibodies. Viruses. 16(4). 596–596. 2 indexed citations

Krohn, Steffen, Claudia D. Baldus, Monika Brüggemann, et al.. (2024). Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia. Blood. 144(Supplement 1). 4173–4173. 1 indexed citations

Klausz, Katja, André Frenzel, Steffen Krohn, et al.. (2023). Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells. Frontiers in Immunology. 14. 10 indexed citations

Pekar, Lukas, Simon Krah, Katja Klausz, et al.. (2023). NKp46‐specific single domain antibodies enable facile engineering of various potent NK cell engager formats. Protein Science. 32(3). e4593–e4593. 19 indexed citations

Arndt, Christian, Thies Rösner, Katja Klausz, et al.. (2022). Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab. Frontiers in Immunology. 13. 949140–949140. 11 indexed citations

Krohn, Steffen, Elisa Cappuzzello, Anja Lux, et al.. (2022). Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody. Frontiers in Immunology. 13. 957874–957874. 6 indexed citations

Peipp, Matthias, et al.. (2022). Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer. Clinical & Experimental Immunology. 209(1). 22–32. 21 indexed citations

Lenk, Lennart, Fotini Vogiatzi, Fabian‐Simon Frielitz, et al.. (2021). Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In Vivo. Journal of Clinical Medicine. 10(12). 2634–2634. 5 indexed citations

10.

Evers, Mitchell, Thies Rösner, J.H. Marco Jansen, et al.. (2021). The selection of variable regions affects effector mechanisms of IgA antibodies against CD20. Blood Advances. 5(19). 3807–3820. 11 indexed citations

11.

Rösner, Thies, Katja Klausz, Christian Kellner, et al.. (2019). Blockade of CD47-Sirpα Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab. Blood. 134(Supplement_1). 5305–5305. 1 indexed citations

12.

Gantke, Thorsten, Uwe Reusch, Christian Kellner, et al.. (2017). AFM26 - Targeting B Cell Maturation Antigen (BCMA) for NK Cell-Mediated Immunotherapy of Multiple Myeloma. Blood. 130. 3082–3082. 6 indexed citations

13.

Klausz, Katja, Steffen Krohn, Renate Burger, et al.. (2017). CD75s Represents a Therapeutic Target for Antibody-Based Immunotherapy of B Cell Lymphoma and Multiple Myeloma. Blood. 130. 1810–1810. 1 indexed citations

14.

Lohse, Stefan, Saskia Meyer, Laura A.P.M. Meulenbroek, et al.. (2015). An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo. Cancer Research. 76(2). 403–417. 62 indexed citations

15.

Peipp, Matthias, Stefanie Derer, Stefan Lohse, et al.. (2015). HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity. Oncotarget. 6(31). 32075–32088. 31 indexed citations

16.

Burger, Renate, et al.. (2014). Effect of targeting the gp130 receptor rather than the IL-6 receptor on control of multiple myeloma growth.. Journal of Clinical Oncology. 32(15_suppl). e19576–e19576. 1 indexed citations

17.

Derer, Stefanie, Stefan Lohse, Katja Klausz, et al.. (2013). Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity. mAbs. 6(2). 409–421. 46 indexed citations

18.

Derer, Stefanie, Sven Berger, Tanja Schneider‐Merck, et al.. (2012). Oncogenic KRAS Impairs EGFR Antibodies' Efficiency by C/EBPβ-Dependent Suppression of EGFR Expression. Neoplasia. 14(3). 190–IN7. 18 indexed citations

19.

Klausz, Katja, Sven Berger, Jeroen J. Lammerts van Bueren, et al.. (2011). Complement‐mediated tumor‐specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). Cancer Science. 102(10). 1761–1768. 26 indexed citations

20.

Berger, Sven, Stefanie Derer, Katja Klausz, et al.. (2010). Fc‐engineered EGF‐R antibodies mediate improved antibody‐dependent cellular cytotoxicity (ADCC) against KRAS‐mutated tumor cells. Cancer Science. 101(5). 1080–1088. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact